Pain Awareness Empowerment

POPF September is pain awareness month

For a healthy person, pain is a warning signal that something is wrong. For a chronic pain patient, it is a state of being. A VERY unpleasant state of being, but one none the less they identify with because they cannot avoid it. They wake up in pain, work all day in pain, sleep in pain if they can sleep at all.

POPF September is pain awareness month
POPF September is pain awareness month

Living in pain is not a small feat for anyone. Existing this world, transgressing the difficulties of being disabled due to an invisible illness or even those with it visible, it is a difficult and awkward time of life. So groups like iPain and US Pain Foundation have a month they celebrate those warriors who keep on fighting, called pain awareness month. That month started yesterday.

We all likely know someone in pain, but may not even know it. So I challenge each person to post something about how you support those with chronic pain, as you would someone with mental illness or diabetes. Help them know that they can come to you if they want to talk about it.

The best thing we can do in our lives is empowering others and empower ourselves. Learning doesn’t have to stop when we graduate high school or college. We have opportunities EVERY DAY. So I challenge you to LEARN about others conditions. You might just save a life knowing more about someone else and what they deal with.

No Comments

Enrollment of the First Patient in a Phase 3 of AXS-02

Doctor

NEW YORK, Aug. 10, 2015 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the treatment of pain and other central nervous system (CNS) disorders, today announced the enrollment of the first patient in the CREATE-1 (CRPS Treatment Evaluation 1) study—a Phase 3 trial evaluating the efficacy and safety of AXS-02 (disodium zoledronate) for the treatment of pain associated with complex regional pain syndrome (CRPS). AXS-02 is a potent osteoclast inhibitor being developed as an oral, targeted, non-opioid, potentially first-in-class therapeutic for chronic pain.

“CRPS patients live with a level of pain that is unimaginable for most of us. As there are no approved treatments for this serious disease, it represents a high unmet medical need,” said Leonardo Kapural, M.D., Ph.D., Professor of Anesthesiology at Wake Forest University, and Clinical Director of the Chronic Pain Center at Wake Forest University Health Sciences Center. “This is an important clinical trial as it may increase the treatment options for those living with CRPS.”

“The Reflex Sympathetic Dystrophy Syndrome Association (RSDSA) supports research to develop better treatments and a cure for this devastating condition,” said Jim Broatch, Executive Vice President and Director of the RSDSA. “Clinical trials such as the CREATE-1 study is an example of the type of research that could yield new options to improve the lives of individuals with CRPS.”

“We are pleased to enroll the first patient in the CREATE-1 trial,” said Randall Kaye, M.D., Chief Medical Officer of Axsome Therapeutics. “This multi-national study will further our understanding of the potential role of AXS-02 in the treatment of pain associated with CRPS. The launch of this Phase 3 trial comes on the heels of our recent FDA Fast Track designation for AXS-02 in CRPS.”

In March of this year, the United States Food and Drug Administration (FDA) granted Fast Track designation for AXS-02 for the treatment of pain associated with CRPS. This designation provides greater access to and more frequent communication with the FDA throughout the entire drug development and review process, with the goal of possibly expediting approval. Fast Track designation also gives Axsome the opportunity to potentially submit sections of the AXS-02 new drug application (NDA) for CRPS on a rolling basis, and allows AXS-02 to be considered for priority review at the time of submission. AXS-02 has also been granted Orphan Drug Designation by the FDA, and Orphan Medicinal Product Designation by the European Medicine Agency (EMA) for the treatment of CRPS.

“As an organization, we aim to research and bring to market innovative therapies for sufferers of chronic pain and CNS diseases,” said Herriot Tabuteau, M.D., Chief Executive Officer of Axsome Therapeutics. “We are committed to working to find solutions for the CRPS patient community.”

About the CREATE-1 Study

This Phase 3 multi-national, multi-center, randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy and safety of AXS-02 in the treatment of pain associated with CRPS. The study is expected to enroll 190 patients at sites in the United States, Canada, Europe, and Australia. Eligible patients will be randomized in a 1:1 ratio to be treated with AXS-02 or placebo. The primary efficacy measure is the change in patient reported pain intensity, measured using the 0-10 Numerical Rating Scale (NRS). Secondary outcome measures include assessments of the change in the Brief Pain Inventory (BPI) Pain Score, Patients’ and Clinicians’ Global Impression of Change (PGI-C and CGI-C, respectively), quality of life measures, and bone turnover markers.

More information about the CREATE-1 study is available at www.clinicaltrials.gov.

To learn about eligibility, patients can visit www.CRPStrial.com.

About AXS-02

AXS-02 (disodium zoledronate) is a potent osteoclast inhibitor being developed as an oral, targeted, non-opioid, potentially first-in-class therapeutic for chronic pain, including pain associated with CRPS. AXS-02 has a high affinity for bone mineral, and reduces osteoclast activity by inhibiting the farnesyl pyrophosphate synthase (FPPS) enzyme.

AXS-02 is an investigational medication not approved by the FDA. The safety and efficacy of AXS-02 have not yet been established.

 

Source: CRPS in the News
Announcement made: August 10, 2015 06:30 ET by Axsome Therapeutics, Inc.
(Copied as online data is not static and this should be retained, please know, all rights are to the author and original publication)

 

New Study, Medication Gives Hope to CRPS-RSD Victims – Legal Examiner

Medicines
Bryan Pope | Attorney • (972) 774-9883
Bryan Pope | Attorney • (972) 774-9883

Axsome Therapeutics, Inc., a biopharmaceutical company dedicated to developing therapies for the treatment of pain and other central nervous system disorders, announced last month that the first patient has been enrolled in the CREATE-1 (CRPS Treatment Evaluation 1) study, a Phase 3 trial evaluating the effectiveness and safety of disodium zoledronate (AXS-02) in the treatment of the pain associated with complex regional pain syndrome (CRPS), also known as reflex sympathetic dystrophy (RSD).

The CREATE-1 study is expected to enroll 190 patients at sites in the U.S., Canada, Europe, and Australia. Eligible patients will be treated with either AXS-02 or a placebo, and the primary objective will be to measure the change in patient-reported pain intensity, measured with the Numerical Rating Scale.

FDA Fast Tracks AXS-02

In March 2015, the U.S. Food and Drug Administration (FDA) granted “Fast Track” designation to AXS-02 for the treatment of the pain associated with CRPS/RSD. AXS-02 is an osteoclast inhibitor being developed as an oral, non-opiod medication to treat the chronic pain. It is an investigational medication not yet approved by the FDA, and its safety and efficacy have not yet been determined. Read more here…

Source: CRPS In the News

(Copied as online data is not static and this should be retained, please know, all right are to the author and her original publication)

Milton Keynes MP Iain Stewart to brief parliament about chronic pain condition

08/05/13 Iain Stewart - westminster, london MP Iain Stewart

Iain Stewart MP will be hosting a MPs briefing session in Parliament on the chronic pain condition Complex Regional Pain Syndrome – most commonly known as CRPS.

08/05/13 Iain Stewart - westminster, london MP Iain Stewart
UK’s MP Iain Stewart is going to address parliament on our UK pain family

CRPS is a progressive disease of the nervous system in which a person develops a persistent burning pain in one or more of their limbs. The NHS describe it as ‘a poorly understood condition’ that ‘may go undiagnosed or misdiagnosed’.

The campaign to raise awareness of CRPS first started when Mr Stewart was contacted by Netherfield resident Kevin Scardifield.

Mr Scardifield,aged 59, was diagnosed with CPRS in August 2009 and as a result he is now crippled and housebound.

Mr Scardifield contacted the MP who then brought up CPRS in a parliamentary debate with the Minister of State at the Department of Health Norman Lamb.

Since the debate Mr Stewart has met with leading health figures including Professor Candy McCabe, Chair of the CPRS UK Network.

Commenting on the MPs briefing Iain Stewart said: “This is a significant step for sufferers. It is seldom discussed in Parliament so I am keen we increase awareness of CPRS at every opportunity.

“Kevin has been an assiduous campaigner and none of this would have been possible without him.”

Mr Scardifield added: “I am hopeful this will be the stepping stone to getting Government to acknowledge CPRS is devastating thousands of lives across the UK and give sufferers the support they need.

“I have been disappointed with the Department of Health’s actions so far but I am confident with the backing from Iain Stewart and other MPs we can get there.”

 

By MKWeb  |  Last updated: March 24, 2015

Read more: http://www.mkweb.co.uk/CPRS-Milton-Keynes-MP-Iain-Stewart-brief/story-26218574-detail/story.html#ixzz3VRYrsqLx

Source: CRPS in the News

Ozone Therapy: Hope for Chronic Illnesses

News

Tags:

Progress

When patients come to Howard Robins, they have been sick for a long time, they’ve tried conventional treatments, and they are running out of hope. They come to him with chronic fatigue, lupus, herpes, Lyme disease, fibromyalgia, cancer, arthritis, multiple sclerosis, and more.

Very often, they leave his care not only with hope, but with their health restored.
Robins, an international expert in natural healing, is one of the world’s leading practitioners of ozone therapy, a technique in which a patient’s blood is infused with medical grade oxygen (O2) and ozone (O3).
“The people who are coming to me have pretty much given up,” Robins tells Newsmax Health. “They find out ozone exists and that it might have a chance to help them.”
In most cases, it works wonders, he says.
“The earlier a person comes in with any condition, the better we can fix them,” he says. “If it’s not too late, then we can turn it around, sometimes to the point where they don’t have any symptoms anymore.”
Ozone was first used in medicine at the end of the 19th century to treat tuberculosis.
During World War I, medics used it to disinfect wounds. Since the 1950s, ozone therapy has gained popularity throughout the world. More than 45,000 physicians in 50 countries now administer ozone.
Ozone is typically administered with one of two different IV methods:
Major Auto-Hemotherapy (MAH), in which blood is drawn from the patient, exposed to ozone and re-injected into the patient.
 
Direct Intravenous Ozone Therapy (DIV), in which oxygen and ozone are directly infused into the patient’s bloodstream.
Although MAH improves many diseases and conditions, it rarely eliminates them. So many doctors prefer DIV, which is safer to perform, yet more powerful in its effects.
“DIV is the only way you can get rid of something,” says Robins.
According to proponents, ozone therapy is broadly effective because it attacks and removes disease-causing agents, including viruses, bacteria, fungi, molds, yeast, and toxic metals.
Because ozone is an oxygen molecule without an electron, it is attracted to electron-rich microorganisms. After it strips away the organisms’ electrons, the cause of the disease dies.
Healthy human cells aren’t affected because they produce antioxidants that make them impervious to ozone.
Ozone also has the ability to chelate toxic metals such as lead, mercury, aluminum, and arsenic, a process which transforms the metals into oxides that are excreted from the body in urine.
Ozone is used to treat:
Infectious diseases such as candida, Epstein-Barr, hepatitis B and C, herpes 1 and 2, herpes zoster, HIV/AIDS, Lyme disease, measles, and pneumonia.
 
Chronic conditions such as Alzheimer’s disease, arthritis, cancer, chronic fatigue syndrome, chronic regional pain syndrome (CRPS), dementia, fibromyalgia, heart disease, lupus, multiple sclerosis, reflex sympathetic dystrophy (RSD), and scleroderma.
 
Eye problems such as conjunctivitis, diabetic retinopathy, dry eye, glaucoma, and macular degeneration.
 
Skin problems such as acne and eczema.
Although ozone therapy is often denigrated by mainstream physicians in the U.S., in other countries such as Germany, it is considered safe and a standard of care.
“When people ask why ozone therapy isn’t more available in the United States, I say it’s because it’s not a patentable medicine and the drug companies can’t make any money off it,” says Robins. “That’s probably the main reason why it’s been suppressed.”
For a list of ozone therapists, go to oxygentherapyexperts.com.
By Rick Ansorge  of Newsmax Health on Friday, 20 Mar 2015 09:00 AM

Source: RSD in the News (Brought to you by Google)

A closer look at pain – The Robesonian

News

Tags:

Questions to ask your Doctor

A Closer Look at Pain

By Kailash Chandwani

According to a report by the Institute of Medicine, the number of Americans affected by pain is more than the total affected by diabetes, heart disease and cancer combined. Pain is classified into acute and chronic, based on the duration of symptoms.

Dr. Kailash Chandwani is an interventional pain physician and is certified in anesthesiology.
Dr. Kailash Chandwani is an interventional pain physician and is certified in anesthesiology.

Acute pain is temporary and usually arises in response to a specific body injury or the sudden onset of an illness. This pain often resolves quickly once the underlying injury is addressed.

Chronic pain is persistent and lasts for three months or longer, and is often challenging to treat. Unrelenting chronic pain may significantly compromise every aspect of an individual’s life — such as physical activity, level of functioning, emotional stability, interpersonal relationships, mood, and sleep. Because of the complex nature of chronic pain, treating it with just one treatment modality is often not as effective as multimodal treatments.

I, Dr. Thomas Florian, and the staff at the Southeastern Spine and Pain use proven and advanced techniques in diagnosing and formulating personalized treatment plans for specific acute and chronic pain. We incorporate a multidisciplinary treatment approach combining knowledge and skills of several health care professionals, including physicians, nurses, pharmacists, and physical and occupational therapists, to reach the desired treatment goal of meaningful pain reduction and improved functioning. We work in collaboration with our patient, primary care physician and other specialty physicians to focus on our patients’ specific needs and to develop a treatment plan.

Some of the conditions we treat include: spine pain (neck, middle and lower back); herniated discs (disc bulge); spinal stenosis; post-laminectomy pain syndrome (persistent pain after back surgery); persistent pain after inguinal hernia repair; head, neck and whiplash pain; postherpetic neuralgia (shingles pain); persistent pain after surgery; myofascial pain; complex regional pain syndrome (Reflex Sympathetic Dystrophy; RSD); muscle and joint pain (e.g., hip & knee); chest wall pain; shoulder and arm pain; phantom limb pain (pain after an amputated limb); arthritis (osteoarthritis, rheumatoid arthritis); peripheral nerve pain; nerve root damage pain and arachnoiditis; multiple sclerosis pain; work-related injuries; central post-stroke pain (pain after a stroke); cancer pain; spasticity; and diabetic peripheral neuropathy.

Our pain clinic within Southeastern Health Park’s new facility at 4901 Dawn Drive, Lumberton, is fully equipped to provide our patients with high quality services. We utilize visual guidance such as fluoroscopy (X-ray) and ultrasound to perform our interventional pain management procedures. Image-guidance has been shown to improve accuracy and clinical outcomes for specific pain conditions.

We utilize our on-site neurophysiology lab to investigate certain types of neuropathic pain in conjunction with other imaging studies. We also work with outpatient rehabilitation program as a part of multidisciplinary approach to restore patients to the highest possible level of mobility and function.

Hospital inpatient services may be utilized — such as a monitored bed unit— as a standard of care for people who are receiving a trial of intrathecal (spinal) drugs to alleviate persistent pain unresponsive to conservative treatments for a select patient population.

Some treatments we offer include: joint injections; under image-guidance (ultrasound and X-ray); epidural steroid injection (cervical, thoracic and lumbar); medial branch blocks for facet joint pain (localized neck and back pain due to spine arthritis); radiofrequency (rhizotomy) for localized neck and back pain due to arthritis; diagnostic lumbar discography; sympathetic and peripheral nerve blocks; implantable devices; and advanced medication management in a safe and effective way. We also offer development of rehabilitation programs which may include physical and occupational therapy and/or psychological counseling.

For information or to schedule an appointment, call 910-671-9298.

Dr. Kailash Chandwani is an interventional pain physician and is certified in anesthesiology.

 

Share and Make Aware would like to thank you for writing an excellent article and covering such a critical topic Kailash Chandwani & The Robesonian

From the February 23. 2015 2:31PM update, if you want/need to see a more updated version, please click the link in the gratitude above

Barby Ingle: Tamper-proof pain drugs deserve support – The Desert Sun

News

Tags:

Medicines

Tamper-proof pain drugs deserve support

Barby Ingle, Special to The Desert Sun 3:04 p.m. PST February 28, 2015

It’s no secret that the abuse of pain medications has led to a growing public health problem across the country. The numbers are alarming, and they are growing.

But also alarming is the number of people who suffer with chronic pain, including many who come to the desert seeking the arid climate for relief.

Tamper-proof Medicine
Tamper-proof medicine will help in more ways then one

The problems are complex and multi-layered and I always applaud solutions that help to balance pain management with the cost that prescription drug abuse has on society. Promising technological advancements in recent years are proving to be an important part of the battle. Among these are so-called “abuse deterrent formulas” of commonly prescribed narcotic painkillers that are being developed to prevent some of the most deadly forms of pain pill abuse.

Since 2002, I have been battling Reflex Sympathetic Dystrophy (RSD), a progressive neuro-autoimmune condition that affects multiple systems in the body. I know firsthand how difficult the journey for relief can be, particularly the sidelong glances and disbelief from medical professionals. One in three people (116 million) in the United States are affected with a condition that causes pain.

But what if there were medications that can offer pain sufferers relief, while also protecting those who might be prone to abuse them?

There are. These little known, new tamper proof formulas of strong narcotic pain medications provide patients with the same pain relief as conventional opioids, while incorporate breakthrough technology designed to protect against tampering and abuse.

Several states are considering legislation this year to improve and safeguard patient access to these new formulas of painkillers.

Abuse-deterrent formulations have received widespread support as part of a comprehensive effort to combat prescription drug abuse and promote appropriate pain management, including from the Office of National Drug Control Policy, the Community Anti-Drug Coalitions of America, members of Congress, and the National Association of Attorneys General — including California Attorney General Kamala Harris.

Abuse of pain medications has led to a growing public health problem in California and nationwide. Each year approximately 4.5 million Americans use prescription pain medications for non-medical purposes, contributing to more than 16,000 deaths annually.

This technology is only part of the solution; but it is a solution nonetheless. Patients that have struggled with addiction or substance abuse in the past, those who live with others who are current or recovering addicts and those who live with teens or young adults who may seek opioids for recreational use can all benefit from ADFs.

Abuse-deterrent formulations have received widespread support as part of a comprehensive effort to combat prescription drug abuse and promote appropriate pain management, including support from the Office of National Drug Control Policy, the Community Anti-Drug Coalitions of America, members of Congress and the National Association of Attorneys General.

To date, the Food and Drug Administration (FDA) has approved abuse-deterrent labeling for four drugs, with other abuse-deterrent opioids in various stages of development.

For the sake of those with legitimate, life-altering pain and for the safety of those prone to use these medications for non-medical use, I urge our lawmakers to stand up for policies that preserve and improve patient access to this new technology. Failing to do so would be failing to do all we can to protect our residents.

Barby Ingle is a chronic pain educator, patient advocate and chairman of the board for the Power of Pain Foundation.
Thanks Barby Ingle for such a inspiring aricle on the fact that Tamper-proof pain drugs deserve support – The Desert Sun

Source: RSD in the News (Brought to you by Google)

 

 

Complex Regional Pain Syndrome Diagnosis using the Budapest Criteria

PainScale

It is complex regional pain syndrome that brings many of us to this site. Many searching for some sort of way to explain where it comes from, what can be done to reverse it, what have medical professionals learned since we were diagnosed. Well medical professionals Konzelmann MDeriaz O, and Luthi F have come together to create an article on the success and utilization of a new diagnosing process. It is called the “Budapest Criteria” which is used to identify complex regional pain syndrome in its earlier stages.

Pain and How the Body Identifies It
Pain and How the Body Identifies It

How does this criteria help those with complex regional pain syndrome

With a successful process to diagnose patients, medical physicians might have a chance to catch patients earlier. And with a solid process this can be targeted and educated to those in the medical fields where doctors might see it most prevalent, emergency rooms and family physicians.

Who did their study focus on?

Their focus was on the partial form of complex regional pain syndrome type one (also known as reflexive sympathetic dystrophy). The specific target was those involving symptoms in only 1-3 fingers, a fairly uncommon occurrence with those with this condition. In the 5 years of their evaluating and observing patients in a rehabilitation ward their results had a fairly solid success rate. They applied this criteria to the evaluation of the radiological exams, the therapeutic results and vocational outcomes of the patients over time.

Of the 132 patients submitted with the diagnosis complex regional pain syndrome, only 16 were met the criteria where it effected only 1-3 fingers. Of these 16 people, 11 were men, 5 women with an average age of 43 years. While reviewing their progress, medical charts and success in therapy, 14 (88%) initially met the Budapest criteria and the other two were verified using a 3 phase bone scan. Now for the majority of the patients, only moderate improvement was made, and at the final follow-up, only 50% had returned to work.

PainScale
The current pain scale rating system used in the United States

What all did they review?

The physicians also compared against literature reviews, which had 19 cases eligible for comparisons. The largest differences is the increased number of male patients in this study, the later diagnosis, and a worse prognosis in the terms of return to work.

With this study and the literature already on file to review, the criteria’s success of diagnosis in 88% of the cases is a very good sign that there is a better chance on the horizon of catching new cases earlier. In turn allowing future patients a better chance of a normal and easier life with RSD than those already diagnosed. It also validated that the three-phase bone scan can only be used in doubtful cases in the first six months of the illness. And thought the partial formation of complex regional pain syndrome type 1 in the hand is rare and the prevalence being unknown. The long-term prognosis, (4 to 9 years) still suggest that earlier diagnosis is beneficial to patients abilities to returning to work.

How do I know this is information is true?

If you would like to read the full article, it can be found here: “Diagnosis of partial complex regional pain syndrome type 1 of the hand: retrospective study of 16 cases and literature review.” BMC Neurol. 2013 Mar 18;13:28. doi: 10.1186/1471-2377-13-28.

Where do I find more articles on complex regional pain syndrome?

More articles can be found at the National Institute of Health’s Library.

No Comments

FDA launches a new program called BeSafeRx

Online pharmacies BeSafeRx

If it seems too good to be true, it probably is. So why are you ordering your medications online? Well to be frank, many of us can’t afford the medication as it costs in the local store. Either because we are denied insurance due to chronic health conditions, or simply all the treatments are so expensive we don’t have any money left for our every day medication costs. Because of this, the FDA has launched a program called BeSafeRx.

BeSafeRx banner

So many people are being scammed into taking sugar pills that they are paying far, far too much for.  In some cases, even worse.  They are taking discarded or old, out-of-date medication that could kill the user. Now, granted many with RSD might not always see the second one as that terrible of a thing when we are at our worst points. But bad medication is not how any of us want to go.

But consider this. If they are lying about your medicine, what would stop them from using that payment information to steal your identity. When you purchase your medicine, you give a pharmacy your name, your birth date, your address, your credit card. This is more than it takes to steal your identity.

The FDA has created a list of some simple ways to quickly spot a scam:

Online pharmacies BeSafeRxWARNING! Beware of online pharmacies that:

  • Allow you to buy drugs without a prescription from your doctor
  • Offer deep discounts or cheap prices that seem too good to be true
  • Send spam or unsolicited email offering cheap drugs
  • Are located outside of the United States
  • Are not licensed in the United States

These are signs of a fake online pharmacy.
Tips for identifying safe online pharmacies:

  • Always require a doctor’s prescription
  • Provide a physical address and telephone number in the United States
  • Offer a pharmacist to answer your questions
  • Have a license with your state board of pharmacy.
    Find your state’s pharmacy licensing database.

These are signs of a safe, legal online pharmacy.

Check your online pharmacy.

I know price can be a big reason to want to get our medicine through other ways, like online. But in the end we have to put our long term health and safety first.

No Comments